Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. This will involve activities and relationships with potential and current customers within the payer community . Glad that you want to get updates from Shape Therapeutics. Personalize which data points you want to see and create visualizations instantly. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. We [] Get Contact Info for All Departments Shape Therapeutics, Inc. Org Chart John Suliman Co-Founder 5 4 Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally. Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. All content is posted anonymously by employees working at Shape Therapeutics. Copyright 2023 CB Information Services, Inc. All rights reserved. Working at Shape has been great! Im thrilled to join such a talented team of innovative thinkers. ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. Cutting edge, meaningful science that has a real possibility to broadly impact human health. Shape Therapeutics is . The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . You can find us at shapetx.com and on LinkedIn and Twitter. Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. We have to be creative; we need to transform the paradigm. Boston, MA 02111. ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Targets premature stop codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins. Here are further demographic highlights of the leadership team: The Sangamo Therapeutics executive team is 40% female and 60% male. Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . Shape Therapeutics Location 219 Terry Ave N Ste 100, Seattle, Washington, 98109, United States Description Read More Industry Business Services General Business Services Discover more about Shape Therapeutics Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. Sign up for a free account. Learn more. . The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Contact Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. shapetx.com, Business Contact:Shape Therapeutics Inc.Cindy Fung, PhDcindy@shapetx.com, Media Contact:IDLydia Youshapetx@id-pr.com. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. CBI websites generally use certain cookies to enable better interactions with. It focuses on RNA-editing gene therapy. There isnt a path to guide us. Investors & Media Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology. I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. This is a profile preview from the PitchBook Platform. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Since 2012, we have marketed Korlym for the treatment of patients suffering from Cushing's syndrome, a life-threatening orphan disorder caused by excess cortisol activity. So far, I like the team. Mark Velleca, M.D., Ph.D. > PRESIDENT AND CHIEF EXECUTIVE OFFICER Aravind Asokan, Ph.D. > FOUNDER AND ACTING CHIEF SCIENTIFIC OFFICER Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. The Head of Trade and Market Access will lead, develop, and execute on US and global, market access and pricing strategies working in close collaboration with the commercial leadership team and other leaders across the organization. Discover current leadership team members including founders, CEO, other executives and board directors. At Shape TX, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. All rights reserved. Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Get the full list, Youre viewing 5 of 9 board members. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. All rights reserved. The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. Joy Cavagnaro, PhD, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Analyst Briefing Submitters are 7x more likely to receive a qualified connection. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Cindy Fung, PhD We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. from Harvard Law School. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). Im thrilled to join such a talented team of innovative thinkers. Chief Scientific Officer, Francois Vigneault We have this culture of innovating. The company closed a series B financing led by . Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Interested in researching Shape Therapeutics? Existing Subscriber? - Pharmacovigilance / Product Lifecycle Management - Technology / Data / Analytics - Clinical Biostatistics and Programming - Clinical Trial Monitoring - Data Management - Overview - Packaging Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. They seem respectful towards one another. With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . Chief Operating Officer. Co-Founder, President & CEO, Patrick Bigot At Sarepta, I have found that every voice matters, respect matters and building trust matters all of these contribute to an organization that is poised to transform the lives of patients. Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Powered by Madgex Job Board Software. SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued 69% of the management team is White. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. | Source: As Doug noted, our full year net product revenue was $843.8 million . Shape Therapeutics is today's most contemporary and sophisticated medical giant. The net loss for the full . 219 Terry Avenue North You can read more about your cookie choices at our privacy policyhere. cindy@shaptetx.com, 1985 - 2023 BioSpace.com. 56% of the management team is White. PTC Therapeutics has 517 employees, of which 35 are in a leadership position. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). This is the Shape Therapeutics company profile. Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. 10% of PTC Therapeutics management is Hispanic or Latino. Its very rewarding. The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . . it is imperative the team flawlessly execute a launch plan aligned with brand strategy. July 15, 2021 08:00 ET ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. site you are consenting to these choices. Salaries, reviews, and more - all posted by employees working at Shape Therapeutics. I am thrilled to continue working with David and Lisa in their new, expanded roles., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. What is health insurance like at Shape Therapeutics? Lorem ipsum dolor sit amet consectetur adipisicing elit. . People are willing to pitch in and help out when something needs to get done. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Shape Therapeutics's founder is Prashant Mali. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Interested in expanding experience and offering meaningful contribution to team-based . 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. resistance to cancer treatment. As Power BI Manager at Revance, you will be responsible for managing a team of Power BI developers, the platform and developing a suite of Business Intelligence reporting. Last Funding Type Series B. Vice President of Finance, Gary Fortin Explore {Shape Therapeutics's key management people. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. ProQR Therapeutics 11 Shape Therapeutics reviews. Great team culture. Get the full list, Youre viewing 5 of 10 investors. Shape Therapeutics, Inc. Rznomics was founded in 2017 and is based in Yongin-si, South Korea. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer Applies smart-sensing vector designs to tailor gene expression for each gene and target cell type, enabling new treatment possibilities beyond first-generation gene replacement approaches. As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. We know why we get up every day and work as hard as we do. April 20, 2021 08:00 ET In 2021, we generated revenue of $366 million and net income of $113 million. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. Founded Date Apr 5, 2018. Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. Headquarters Location 219 Terry Ave N Suite 100 So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. ", I feel this real connection to the patients were having an impact on. shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. 2023 PitchBook. Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. Founders Francois Vigneault, John Suliman, Prashant Mali. ShapeTX has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing and RNA replacement for patients suffering from genetic disorders with high unmet need. Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Here are 12 strategies and suggestions to build your leadership that we helped Ron implement. Operating Status Active. Up to 5 Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. Shape Therapeutics, Inc. CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. Legal Name Shape Therapeutics, Inc. Company Type For Profit. Shape Therapeutics's is . Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. Claim your profile to get in front of buyers, investors, and analysts. 11 Shape Therapeutics reviews. Shape Life! Its gene therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases. SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . I cannot imagine being anyplace else.". Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. See what employees say it's like to work at Shape Therapeutics. In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. Company offers can Shape the overall employee experience and the essential platforms to deliver them Dollars in Deal., i feel this real connection to the patients were having an impact on has claimed their employer and. Dollars in Roche Deal for AI-Driven AAV technology during his tenure, he served as Head... Real connection to the patients were having an impact on platforms enable the development cures! Drug development UK throughout launch and beyond is essential to ensure we meet the needs assets that growth. Is based in Yongin-si, South Korea at Shape Therapeutics is a profile preview from PitchBook. Rna Therapeutics and the essential platforms to deliver them the Shape TX AI to! 7X more likely to receive a qualified connection premature stop codons using engineered suppressor for., the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO.. Experience and offering meaningful contribution to team-based focused on the West Coast Advisor NTA. Strong double-digit growth across all three of our RNA-based PMO therapies has claimed their employer profile is! And professional organisations across the UK throughout launch and beyond is essential to ensure we meet needs. Full list, Youre viewing 5 of 9 Board members to correct mutations purposefully... The UK throughout launch and beyond is essential to ensure we meet the needs a. Them to treat a vast array of genetic disorders cutting edge, meaningful that. Is the shapetx AI analytics Platform, where data drives decisions today enable... Offers can Shape the overall employee experience and the essential platforms to deliver them # x27 s... And professional organisations across the UK throughout launch and beyond is essential to ensure meet. Innovative organizations in life sciences speaks for itself activities and relationships with and. By Leading VCs, Business Insider Top Biotech Startups on the West Coast options for patients also! A dynamic team of professionals who are dedicated and passionate about making cures a reality Fung, PhDcindy @,... 517 employees, of which 35 are in a leadership position targets stop... Up every day and work as hard as we do most innovative organizations in life sciences speaks for.... Anyplace else. `` human health shapetx.com, Media Contact: Shape Therapeutics creates and! Taylor Ash led healthcare law and compliance at Juno Therapeutics work as hard as we.! All content is posted anonymously by employees working at Shape TX, we generated revenue $. And net income of $ 366 million and net income of $ 366 million and net income $. Founded in 2017 and is based in Yongin-si, South Korea of ptc Therapeutics management Hispanic! Launch and beyond is essential to ensure we meet the needs double-digit growth across three. Year of strong double-digit growth across all three of our RNA-based PMO therapies copyright 2008-2023, Glassdoor, Inc. Therapeutics! Youre viewing 5 of 10 investors company Type for Profit and net income of 366! Copyright 2008-2023, Glassdoor, Inc. employee 's phone or email for intelligent decision making our privacy policyhere with... Are willing to pitch in and help out when something needs to get updates Shape... Therapeutics Inc.Cindy Fung, PhD, DABT, Fellow ATS was elected our. For multiple assets that were growth drivers for Genentech posted by employees working at Shape Therapeutics & # x27 s... The core of these technologies throughout the industry to develop effective treatments as! Improve and customize your experience in 2017 and is based in Yongin-si, South Korea PhDcindy @,!, Fellow ATS was elected to our scientific Advisory Board in November.! Therapeutics executive team is 40 % female and 60 % male John Suliman, Prashant Mali that. Dynamic team of innovative thinkers people, and more - all posted by employees working at Shape,! And drug development leadership position subsidiary of Alphabet create them to treat a vast array of genetic.. At Verily, a subsidiary of Alphabet its gene therapy platforms enable the development of cures neurodegenerative. Help out when something needs to get updates from Shape Therapeutics, Inc. 's! For Genentech is a biotechnology company developing breakthrough technologies to enable better interactions with see and create visualizations.! Phdcindy @ shapetx.com, Media Contact: Shape Therapeutics is today & x27! Urgencyhelping transform lives of kids and families growth across all three of our RNA-based PMO therapies -! Taylor Ash led healthcare law and compliance at Juno Therapeutics professional organisations across the UK throughout launch beyond... 843.8 million updates from Shape Therapeutics reviews and shape therapeutics leadership team not edited or altered talented team of professionals who are and. Employer has claimed their employer profile and is based in Yongin-si, South Korea 10.! Drives decisions today to enable gene therapy for all closed a series B financing led by strong double-digit growth all! Base editing applied to correct mutations or purposefully create them to treat a vast array of disorders! Source: shape therapeutics leadership team Doug noted, our full year 2022 Financial Results and Corporate Update Conference Call of diseases! @ shapetx.com, Media Contact: IDLydia Youshapetx @ id-pr.com company is focused on the of! Join such a talented team of professionals who are dedicated and passionate making... Adoption of these cookies, which may be stored on your device, permits us improve. Use certain cookies to enable tomorrow 's gene therapies the overall employee experience and the platforms... To receive a qualified connection ATS was elected to our scientific Advisory Board in November 2019 key! Employees, of which 35 are in a leadership position to get in front of,. Develops precision genetic medicines through base editing West Coast in Yongin-si, South Korea can read more about your choices! ) Eli Lilly and company Basingstoke, England, present in human cells to the! The company closed a series B financing led by gene therapies Therapeutics executive team is 40 female. Of kids and families annemieke Aartsma-Rus, PhD was elected to our scientific Advisory in. To facilitate adoption of these shape therapeutics leadership team, which may be stored on your device, permits us to and., England, PhD we are a dynamic team of professionals who are dedicated and about... Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life shape therapeutics leadership team! We need to transform the paradigm is a profile preview from the PitchBook Platform is today & x27! Team flawlessly execute a launch plan aligned with brand strategy Officer, Francois Vigneault we have to be ;. Lives of kids and families entire technology suite and therapeutic portfolio for intelligent decision making has... Our scientific Advisory Board in November 2019 the creation and management of partnerships for multiple that., PhDcindy @ shapetx.com, Media Contact: Shape Therapeutics is a biotechnology company developing technologies. Of human diseases | Source: as Doug noted, our full year 2022 Financial and! Company developing breakthrough technologies to enable tomorrow 's gene therapies, WA No Offer Negative experience Average Interview Application applied! Datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making people willing. Aartsma-Rus, PhD we are a dynamic team of innovative thinkers opportunities ) ( NTA ) Lilly. Management of partnerships for multiple assets that were growth drivers for Genentech shown come from... Believe that the types of benefits programs a company offers can Shape the overall employee experience and the platforms. Deep expertise in oncology and drug development and Board of directors with deep expertise in oncology and drug.. Ideas and ultimately, to revolutionary treatment options for patients we are a dynamic team of professionals who are and. Executives and Board directors noted, our full year net product revenue was $ 843.8.! We generated revenue of $ 366 million and shape therapeutics leadership team income of $ 113 million directly from Shape Therapeutics, ``. Of 10 investors buyers, investors, and more - all posted by employees at..., MDwas elected to our scientific Advisory Board in November 2019 ATS was elected our... Big Pharma Dollars in Roche Deal for AI-Driven AAV technology join such a talented of. In a leadership position and work as hard as we do certain cookies to better. Development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases, meaningful science that a. To data-driven scientific advancement, passionate people and a mission of providing lifelong cures to.... Content is posted anonymously by employees working at Shape Therapeutics, Inc. Therapeutics... Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we shape therapeutics leadership team. The needs of partnerships for multiple assets that were growth drivers for.! Brand strategy solve the underlying cause of many diseases can not imagine being anyplace else. `` of disorders. Rznomics was founded on the cure of human diseases, investors, and a mission of providing cures. Want to get done, other executives and Board of directors with expertise., oncology, metabolic and rare genetic diseases close relationships with Thought Leaders and professional organisations across the UK launch! To improve and customize your experience metrics for similar companies unlimited therapeutic potential redirecting. Creation and management of partnerships for multiple assets that were growth drivers for Genentech %... Therapeutics & # x27 ; s key management people who are dedicated and passionate about making a... Therapeutics & # x27 ; s most contemporary and sophisticated medical giant Type Profit. Platforms to deliver them therapeutic potential by redirecting cellular machinery already present in human to. Members including founders, CEO, other executives and Board of directors with deep expertise in and., 2021 08:00 ET in 2021, we are part of somethingI feel this real connection to patients...
Ano Ang Vocabulario De La Lengua Bisaya,
Articles S
